USPTO 2015–2025 USPTO PatentsView US Corporation

Theranos IP Company, Llc

USPTO PatentsView assignee record — 66 granted patents across 32 technology areas, active 2018–2020. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES).

66
Total patents granted
32
CPC technology areas
17.4
Avg claims per patent
-68%
5-year filing velocity

The verdict

Theranos holds 66 US patents across 32 technology areas — rank #5,253 of 50,000 tracked assignees.

#5,253
of 50,000 US assignees by volume
Top 24%
by Innovation Score (44.9/100)
17.4
avg claims per patent
-68%
filing velocity, last 5 yrs

Portfolio overview

Theranos IP Company, LLC has been granted 66 US utility patents between 2018 and 2020, placing Theranos IP Company, LLC at rank #5,253 across all assignees tracked by PlainPatent. This portfolio spans 32 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.4 claims per patent with primary concentration in G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES). As a US Corporation, Theranos IP Company, LLC is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 44.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 16 grants, compared with 50 in the 2015–2019 window — a -68% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Theranos IP Company, LLC's 17.4 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 32 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Theranos IP Company, LLC against peers pursuing similar technology classes.

How does Theranos compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows Theranos holds 66 patents — placing it at rank #5,253 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

Theranos's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

45 Top 24% higher than 76% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). This entry sits in this band. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2020

15202530 201820192020 16
USPTO utility patent grants by year · 2018–2020

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table
Theranos IP Company, LLC patent grants by year, 2015–2025
Year Patents Granted Share of Period
2018 23 34.8%
2019 27 40.9%
2020 16 24.2%

Which technologies does Theranos IP Company, LLC patent most?

Top 15 of 32 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Multi-domain
Claim Depth Standard
Velocity Declining

Where it ranks

Overall rank by patents

#5,253

Across all tracked assignees

Innovation Score

44.9 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Theranos IP Company, LLC hold?
Theranos IP Company, LLC holds 66 US granted patents filed between 2018 and 2020, spanning 32 technology areas.
What is Theranos IP Company, LLC's Innovation Score?
Theranos IP Company, LLC has an Innovation Score of 44.9 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Theranos IP Company, LLC focus on?
Theranos IP Company, LLC's top technology area is G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES) with 44 patents. The company has filed patents in 32 CPC subclasses total.
Is Theranos IP Company, LLC's patent filing rate increasing or decreasing?
Theranos IP Company, LLC's recent filing velocity is -68% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Theranos IP Company, LLC's patents?
Theranos IP Company, LLC's patents average 17.4 claims each. This falls within the standard range, providing solid legal coverage.
How is the Theranos IP Company, LLC patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

How to use this portfolio

Theranos's 66 grants land it in the top 24% by Innovation Score — but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance — Theranos ranks #5,253 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in G01N — see who else leads that technology area. G01N leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity — not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Data sources used on this page
  • USPTO PatentsView — the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) — the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search — the official interface to verify the status of any individual patent. ppubs.uspto.gov